There is discrepancy between the FDA’s accelerated approval decisions and clinical benefits in cancer treatments; former President Donald Trump’s video statement avoids a clear stance on national abortion legislation; 40% of therapists say they will increase their fees this year.
Limited Benefits of Cancer Drugs Granted Accelerated Approval
A recent study found that most cancer drugs granted accelerated approval by the FDA do not demonstrate significant clinical benefits within 5 years, according to The Associated Press. Despite the program’s intent to expedite access to promising treatments, only 43% of these drugs showed clinical benefit in confirmatory trials, raising concerns about patient understanding and informed decision-making. With recent updates to the program granting the FDA more authority, efforts are underway to ensure faster withdrawal of drugs that fail to meet their commitments.
Trump Defers Abortion Decision to States
In a video posted to Truth Social, former President Donald Trump avoided endorsing federal abortion legislation, instead advocating for state-based decisions on the issue, according to The Hill. While reiterating his support for overturning Roe v Wade and emphasizing his role in appointing conservative Supreme Court justices, his statement remained evasive regarding his stance on signing a federal abortion ban, drawing criticism from both anti-abortion activists and Democrats.
Four in 10 Therapists Plan to Raise Fees in 2024
A survey conducted by Heard revealed that 40% of therapists intend to increase their fees in 2024, with inflation and economic uncertainties being cited as contributing factors, according to Fierce Healthcare. Although most therapists reported earning less than $100,000 in gross income and profit from their practices in 2023, many still offer sliding scale fees or pro bono sessions to ensure accessibility. Additionally, despite the popularity of cash payments, most therapists still accept some form of insurance, with Aetna being the most common payer.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More